臨床検査65巻7号

2021年07月発行

今月の特集 薬物療法に活用される検査

抗腫瘍療法における臨床検査の活用

著者： 堀江沙良¹ 浜本康夫²

所属機関： ¹慶應義塾大学病院消化器内科 ²慶應義塾大学医学部腫瘍センター

ページ範囲：P.736 - P.742

Point

●抗がん剤治療を安全に継続するためには肝障害，腎障害，骨髄抑制などの副作用の評価が不可欠である．血液検査などの臨床検査は抗がん剤の有害事象のモニタリングに使用される．

●薬物代謝酵素の遺伝子多型は薬物に対する生体反応を予測できる．その結果に基づいて抗がん剤の用量調節を行う．

●マイクロサテライト不安定性（MSI），ヒト上皮細胞増殖因子受容体2型（HER2），上皮成長因子受容体（EGFR），RAS，BRAFなどのがん遺伝子異常の検査はがんの診断，予後予測，治療決定に有用である．

参考文献

1）Teng JF, Mabasa VH, Ensom MH：The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit　34：85-97，2012

2）Demetri GD, Wang Y, Wehrle E, et al：Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol　27：3141-3147，2009

3）Postow MA, Callahan MK, Wolchok JD：Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol　33：1974-1982，2015

4）Dabydeen DA, Jagannathan JP, Ramaiya N, et al：Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer　48：1519-1524，2012

5）Russell SD, Blackwell KL, Lawrence J, et al：Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol　28：3416-3421，2010

6）Cairo MS, Bishop M：Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol　127：3-11，2004

7）Goldman SC, Holcenberg JS, Finklestein JZ, et al：A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood　97：2998-3003，2001

8）Coiffier B, Mounier N, Bologna S, et al：Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol　21：4402-4406，2003

9）Ando Y, Saka H, Ando M, et al：Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res　60：6921-6926，2000

10）Minami H, Sai K, Saeki M, et al：Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics　17：497-504，2007

11）Kakuta Y, Kawai Y, Okamoto D, et al：NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol　53：1065-1078，2018

12）Marabelle A, Le DT, Ascierto PA, et al：Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol　38：1-10，2020

13）日本乳癌学会（編）：乳癌診療ガイドライン　②疫学・診断編　2018年版，金原出版，2018

14）Modi S, Saura C, Yamashita T, et al：Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med　382：610-621，2020

15）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet　376：687-697，2010

16）Shitara K, Bang YJ, Iwasa S, et al：Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med　382：2419-2430，2020

17）Dummer R, Ascierto PA, Gogas HJ, et al：Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol　19：1315-1327，2018